Study aims to map how patients and caregivers find information about pulmonary hypertension
NCT ID NCT07207525
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study uses a short questionnaire to learn where patients with pulmonary hypertension and their caregivers search for health information, what topics they look for, how satisfied they are, and which sources they trust most. Researchers will enroll 100 adults in Brazil. The goal is to improve communication and support for those affected by this serious lung condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors and organizations create better educational materials and support programs for people with pulmonary hypertension.
- What could go wrong
- This is an observational study with only 100 participants, so results may not apply to everyone. It does not test any treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Instituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo
São Paulo, São Paulo, 05403-900, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaled therapy replace a daily pill for PAH?
- Can a Real-World registry improve how treprostinil is used for PAH?
- Which PAH treatment strategy works better: adding a third drug or increasing the dose?
- Lung patients may soon do rehab from home via app
- Which drug is best for pulmonary hypertensive crisis? new trial aims to find out
- New PAH drug IKT-001 moves to Long-Term safety check